<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Endocrine dysfunction in the nephrotic syndrome</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Endocrine dysfunction in the nephrotic syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Endocrine dysfunction in the nephrotic syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jai Radhakrishnan, MD, MS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fernando C Fervenza, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 05, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The nephrotic syndrome is characterized by a marked increase in the glomerular permeability to macromolecules. The associated urinary losses of albumin and hormone-binding proteins are responsible for many of the metabolic derangements and endocrine abnormalities in these patients [<a href="#rid1">1</a>].</p><p>This topic review will emphasize the alterations in thyroid, vitamin D, calcium, and glucocorticoid metabolism. The effects on lipid metabolism are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3114.html" rel="external">"Lipid abnormalities in nephrotic syndrome"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">THYROID FUNCTION</span></p><p class="headingAnchor" id="H4241576291"><span class="h2">Alterations in thyroid function</span><span class="headingEndMark"> — </span>In patients with the nephrotic syndrome, thyroid function tests reveal variable results, primarily depending upon the level of protein losses in the urine. In addition, other factors that are frequently present in such patients, such as hypoalbuminemia, increased serum free fatty acid concentrations, and glucocorticoid and <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> administration, can also affect thyroid function tests [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/z/d/html/7891.html" rel="external">"Laboratory assessment of thyroid function"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 50 percent of nephrotic patients with relatively normal kidney function have low total thyroxine (T4) concentrations resulting from urinary losses of T4-binding globulin (TBG) and other thyroid hormone-binding proteins (transthyretin and albumin) and the T4 bound to them [<a href="#rid3">3-5</a>]. Serum triiodothyronine (T3) concentrations may also be low due to decreased binding. There is often a good correlation between the serum T4 and T3 and the serum albumin concentration [<a href="#rid5">5</a>]. Serum reverse T3 (rT3) concentrations are also low.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When impaired kidney function complicates the nephrotic syndrome, the thyroid function test abnormalities are often more severe than when either kidney failure or the nephrotic syndrome is present alone [<a href="#rid6">6</a>]. However, most patients remain clinically euthyroid. (See  <a class="medical medical_review" href="/z/d/html/1977.html" rel="external">"Thyroid function in chronic kidney disease"</a> and  <a class="medical medical_review" href="/z/d/html/7817.html" rel="external">"Thyroid function in nonthyroidal illness"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoids, which are often given to treat the nephrotic syndrome, can cause a small reduction in thyroid-stimulating hormone (TSH) secretion and inhibit the peripheral conversion of T4 to T3. The net effect may be persistently low serum T3 and basal serum TSH concentrations and a rise in serum rT3 concentrations [<a href="#rid7">7</a>]. Thus, the serum free T4 concentrations may be the best marker of thyroid status in patients receiving glucocorticoids, and such patients with low serum free T4 concentrations probably should be treated as if they were hypothyroid [<a href="#rid8">8</a>]. (See <a class="local">'Assessment of thyroid function'</a> below.)</p><p></p><p>In earlier studies, nephrotic patients were usually clinically euthyroid, as evidenced by normal free T3, T4, and TSH levels [<a href="#rid5">5</a>]. However, subsequent reports suggest that thyroid dysfunction may be more common among such patients than previously thought. In a study from China of 317 patients with the nephrotic syndrome, 82 percent had an abnormality on thyroid function testing; of these, 32 percent had hypothyroidism (low free T4 and T3, high TSH levels), 24 percent had subclinical hypothyroidism (normal free T4 and T3, high TSH levels), and 37 percent had euthyroid sick syndrome (low free T3, T4, or both T3 and T4 levels with low, normal, or slightly elevated TSH) [<a href="#rid2">2</a>]. Patients with thyroid dysfunction had higher urine protein levels and dyslipidemia, higher serum creatinine levels, and lower platelet counts.</p><p>Some causes of the nephrotic syndrome are associated with autoimmune thyroid disease. Membranous nephropathy, for example, has been associated with both autoimmune thyroiditis (Hashimoto's disease) [<a href="#rid9">9</a>] and Graves' disease [<a href="#rid10">10</a>]. Antithyroid antibodies have been reported in the glomerular immune deposits in Graves' disease [<a href="#rid11">11</a>], and, in this particular case, thyroidectomy was associated with disappearance of antithyroid antibodies, reduction of proteinuria (but not complete remission), and stabilization of glomerular filtration rate. Conversely, treatment of patients with Graves' disease with radioactive iodine has been associated with the appearance of membranous nephropathy and proliferative glomerulonephritis [<a href="#rid12">12,13</a>]. The mechanisms linking diseases of the kidney and thyroid are not clear.</p><p>Severe hypothyroidism may be associated with kidney function impairment and proteinuria, which reverse after treatment with thyroid hormone replacement [<a href="#rid14">14,15</a>].</p><p class="headingAnchor" id="H1896006716"><span class="h2">Assessment of thyroid function</span><span class="headingEndMark"> — </span>There are no specific guidelines on screening thyroid function in patients with the nephrotic syndrome. In patients with the nephrotic syndrome who do <strong>not</strong> have preexisting thyroid disease, some clinicians routinely test thyroid function by obtaining a serum TSH level when the nephrotic syndrome is first diagnosed and then perform serial testing (at least annually) in patients who remain nephrotic. However, other clinicians do not routinely test thyroid function in all patients with the nephrotic syndrome and reserve testing only for those who have preexisting thyroid disease. If hypothyroidism is suspected clinically in any patient, serum TSH should be measured. (See  <a class="medical medical_review" href="/z/d/html/7891.html" rel="external">"Laboratory assessment of thyroid function", section on 'Evaluating for thyroid dysfunction'</a> and  <a class="medical medical_review" href="/z/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults", section on 'Clinical features'</a>.)</p><p>Patients with preexisting hypothyroidism may experience higher thyroid hormone replacement requirements due to loss of thyroid binding globulin in the urine [<a href="#rid16">16,17</a>]. Such patients should have serum TSH levels tested every six to eight weeks until therapeutic and every six months thereafter. If levels of proteinuria change (eg, with remission of the nephrotic syndrome or with disease relapse), TSH levels should be repeatedly tested as above until stable. </p><p>In view of the possibility of suppressed TSH levels in patients on high doses of glucocorticoids, testing both TSH and free T4 is suggested in hypothyroid patients on thyroid hormone replacement to assess adequacy of replacement while on glucocorticoids. Similarly, both TSH and free T4 levels should be monitored in patients with preexisting hyperthyroidism who are receiving high doses of glucocorticoids to assess hormonal status. (See <a class="local">'Alterations in thyroid function'</a> above.) </p><p class="headingAnchor" id="H1189104021"><span class="h2">Management</span><span class="headingEndMark"> — </span>In general, nephrotic patients with abnormal thyroid function tests do not require thyroid hormone replacement unless they have overt hypothyroidism (ie, high TSH level and low free T4 level) [<a href="#rid5">5</a>]. In patients who have preexisting hypothyroidism, the development of nephrotic syndrome may be associated with increased thyroid hormone requirements. In one case report of a patient who developed clinical hypothyroidism due to refractory nephrotic syndrome, resolution of proteinuria following bilateral nephrectomy led to normalization of thyroid function and cessation of thyroid hormone replacement [<a href="#rid18">18</a>].</p><p>In addition, patients receiving glucocorticoid therapy who have low serum free T4 concentrations probably should be treated as if they were hypothyroid [<a href="#rid8">8</a>]. Interestingly, in a study of 73 nephrotic children with thyroid function abnormalities treated with glucocorticoids, treatment with thyroid replacement was associated with shorter time to remission and higher serum albumin than no thyroid replacement [<a href="#rid19">19</a>].</p><p>A detailed discussion on the treatment of hypothyroidism in adults and children is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults", section on 'Approach to treatment'</a> and  <a class="medical medical_review" href="/z/d/html/5838.html" rel="external">"Acquired hypothyroidism in childhood and adolescence", section on 'Treatment and prognosis'</a>.)</p><p class="headingAnchor" id="H3972073801"><span class="h1">VITAMIN D AND CALCIUM METABOLISM</span></p><p class="headingAnchor" id="H40263393"><span class="h2">Effects on vitamin D and calcium</span><span class="headingEndMark"> — </span>The nephrotic syndrome is associated with urinary loss of vitamin-D-binding protein (VDBP), due to increased permeability of the slit diaphragm in patients with the nephrotic syndrome [<a href="#rid20">20</a>]. In serum, calcidiol (25-hydroxyvitamin D), the precursor of the most active metabolite calcitriol, is primarily bound to VDBP and is therefore also excreted in the urine [<a href="#rid21">21,22</a>] (see  <a class="medical medical_review" href="/z/d/html/2033.html" rel="external">"Overview of vitamin D", section on 'Metabolism'</a>). The net effect is a reduction in serum calcidiol concentrations, while those of calcitriol are normal or reduced [<a href="#rid21">21,23,24</a>]. However, the physiologically important serum free or bioavailable calcidiol concentration is usually normal, suggesting that reduced total concentrations are due to loss of hormone bound to VDBP [<a href="#rid24">24,25</a>].</p><p>The physiologic consequences of these changes in vitamin D metabolism on calcium homeostasis are uncertain. Hypocalcemia is a common finding in the nephrotic syndrome due primarily to hypoalbuminemia-induced reduction in calcium binding to albumin. In general, the serum total calcium concentration will fall approximately 0.8 mg/dL (0.2 mmol/L) for every 1 g/dL (10 g/L) reduction in serum albumin concentration. A low serum total calcium concentration induced by hypoalbuminemia does not affect the physiologically important free (or ionized) calcium concentration. Thus, measurement of the ionized calcium concentration is generally required to confirm hypocalcemia in nephrotic patients with a low total serum calcium.</p><p>Alternatively, the measured serum calcium (Ca) concentration can be corrected for the presence of hypoalbuminemia from the following equation:</p><div class="formulaContainer"><div class="formula"><p>  Corrected [Ca]  =  Measured total [Ca] + 0.8  x  (4.5 - [alb])</p></div></div><p>where the serum calcium and albumin (alb) concentrations are measured in units of mg/dL and g/dL, respectively. Thus, if the measured values are 7.6 mg/dL and 2.5 g/dL:</p><div class="formulaContainer"><div class="formula"><p>  Corrected [Ca]  =  7.6 + 0.8  x  2  =  9.2 mg/dL</p></div></div><p>A subset of patients has been reported with hypocalcemia out of proportion to hypoalbuminemia due to low serum calcitriol concentrations. These patients have a decline in ionized calcium concentrations [<a href="#rid26">26,27</a>] and a secondary elevation in serum parathyroid hormone (PTH) concentrations [<a href="#rid28">28</a>]. The hyperparathyroidism can then lead to bone disease characterized by mixed osteomalacia and osteitis fibrosa [<a href="#rid24">24</a>]. A review of the histologic changes that may be seen can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7239.html" rel="external">"Evaluation of renal osteodystrophy"</a>.)</p><p>The frequency with which true hypocalcemia and bone disease occur in the nephrotic syndrome is unclear as many investigators have found relatively normal calcium and bone metabolism. One report, for example, evaluated six adults with the nephrotic syndrome and normal kidney function [<a href="#rid29">29</a>]. Although serum calcidiol concentrations were reduced, the serum ionized calcium, calcitriol, and PTH concentrations were normal, and there was no histologic evidence of bone disease. Other investigators have also noted normal intestinal calcium absorption and bone histology [<a href="#rid30">30,31</a>].</p><p>In summary, only a subset of patients with the nephrotic syndrome develops clinically important abnormalities in vitamin D, calcium, and bone metabolism. Suggested predisposing factors include increasing age, prolonged duration of disease, kidney function impairment, marked proteinuria, and glucocorticoid therapy [<a href="#rid7">7</a>]. Another possibility that has been demonstrated in experimental animals is impaired production of calcitriol due to tubular damage induced by heavy proteinuria [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H3024801275"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Vitamin D replacement therapy (with <a class="drug drug_general" data-topicid="10150" href="/z/d/drug information/10150.html" rel="external">ergocalciferol</a> or <a class="drug drug_general" data-topicid="10117" href="/z/d/drug information/10117.html" rel="external">cholecalciferol</a>) is not routinely given to all patients with the nephrotic syndrome but may be appropriate in certain settings. We check a baseline serum 25-hydroxyvitamin D level at the time of diagnosis of the nephrotic syndrome and repeat this test every four months if the patient is persistently nephrotic or is receiving treatment with glucocorticoids. We administer vitamin D replacement therapy in patients who are found to have a low serum 25-hydroxyvitamin D level at any time during the course of their disease. In patients who have normal serum 25-hydroxyvitamin D levels, we give vitamin D maintenance therapy to those with persistent or relapsing nephrotic syndrome or who are receiving glucocorticoid therapy. (See  <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Vitamin D replacement'</a> and  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'Calcium and vitamin D'</a>.)</p><p>If vitamin D is given, oral therapy is probably sufficient. Studies in experimental animals with the nephrotic syndrome have found that calcidiol absorption is normal [<a href="#rid33">33</a>]. Similar findings have been noted in humans. In one study, for example, oral administration of calcidiol to nephrotic patients resulted in sustained normalization of the serum calcidiol concentrations and, if kidney function was normal, calcitriol; these changes were accompanied by correction of the low serum ionized calcium concentrations and of secondary hyperparathyroidism [<a href="#rid34">34</a>]. </p><p>Patients with the nephrotic syndrome who develop chronic kidney disease will often be at an increased risk for vitamin D-related bone disease due to the associated reduction in calcitriol synthesis. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6085.html" rel="external">"Chronic kidney disease in children: Overview of management"</a>.)</p><p>Moreover, in patients treated with glucocorticoids, indications for prophylaxis against osteoporosis should be considered. (See  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis"</a>.)</p><p>The effects of the chronic administration of glucocorticoids on bone mineral density in children with the nephrotic syndrome are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6130.html" rel="external">"Treatment of idiopathic nephrotic syndrome in children"</a>.)</p><p class="headingAnchor" id="H2102835063"><span class="h1">GLUCOCORTICOID METABOLISM</span><span class="headingEndMark"> — </span>Cortisol-binding globulin (CBG) also is lost in the urine of nephrotic patients, and serum cortisol concentrations may be reduced. As with thyroxine (T4), however, the percentage of unbound cortisol is increased, serum free cortisol concentrations are normal, and symptomatic hypocortisolism typically does not occur [<a href="#rid35">35</a>].</p><p>However, rare cases of primary adrenal insufficiency in the setting of congenital nephrotic syndrome have been reported, some with adrenal calcifications [<a href="#rid36">36-38</a>]. It has been postulated that severe hypovolemia in patients with congenital nephrotic syndrome could predispose to adrenal infarctions. In addition, a multisystem genetic abnormality (eg, <em>WT1 </em>or <em>SGPL1 </em>pathogenic variants) causing adrenal insufficiency and nephrotic syndrome may be responsible in some cases [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H858625593"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– The nephrotic syndrome is characterized by a marked increase in the glomerular permeability to macromolecules. The associated urinary losses of albumin and hormone-binding proteins are responsible for many of the metabolic derangements and endocrine abnormalities in these patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thyroid function</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alterations in thyroid function </strong>– Approximately 50 percent of patients with the nephrotic syndrome and relatively normal kidney function have low total thyroxine (T4) concentrations resulting from urinary losses of T4-binding globulin (TBG) and other thyroid hormone-binding proteins and the T4 bound to them. Serum triiodothyronine (T3) concentrations may also be low due to decreased binding. While earlier studies suggested that nephrotic patients were usually clinically euthyroid, subsequent reports suggest that thyroid dysfunction may be more common than previously thought. (See <a class="local">'Alterations in thyroid function'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Effects of glucocorticoids </strong>– Glucocorticoids, which are often given to treat the nephrotic syndrome, can also cause a small reduction in thyroid-stimulating hormone (TSH) secretion and inhibit the peripheral conversion of T4 to T3. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Assessing thyroid function </strong>– In patients with the nephrotic syndrome who do <strong>not</strong> have preexisting thyroid disease, some clinicians routinely obtain a serum TSH level when the nephrotic syndrome is first diagnosed and then perform serial testing (at least annually) in patients who remain nephrotic. However, other clinicians reserve thyroid testing only for those who have preexisting thyroid disease. If hypothyroidism is suspected clinically in any patient, serum TSH should be measured. (See <a class="local">'Assessment of thyroid function'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management </strong>– In general, nephrotic patients with abnormal thyroid function tests do not require thyroid hormone replacement unless they have overt hypothyroidism (ie, high TSH level and low free T4 level), in which case the treatment is the same as in patients without nephrotic syndrome. In patients who have preexisting hypothyroidism, the development of nephrotic syndrome may be associated with increased thyroid hormone requirements. Patients receiving glucocorticoid therapy who have low serum free T4 concentrations probably should be treated as if they were hypothyroid. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin D and calcium metabolism</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Effects on vitamin D and calcium </strong>– Serum calcidiol (25-hydroxyvitamin D) and calcitriol concentrations may be reduced in patients with nephrotic syndrome, but the physiologically important serum free or bioavailable calcidiol concentration is usually normal. Hypocalcemia is common, however, due to hypoalbuminemia; this does not affect the physiologically important free (or ionized) calcium concentration. Measurement of the ionized calcium concentration is generally required to confirm hypocalcemia in nephrotic patients with a low total serum calcium. (See <a class="local">'Effects on vitamin D and calcium'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment </strong>– Vitamin D replacement therapy is not routinely given to all patients with the nephrotic syndrome but may be appropriate in certain settings. We administer vitamin D replacement therapy in patients who are found to have a low serum 25-hydroxyvitamin D level at any time during the course of their disease. In patients who have normal serum 25-hydroxyvitamin D levels, we give vitamin D maintenance therapy to those with persistent or relapsing nephrotic syndrome or who are receiving glucocorticoid therapy. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid metabolism </strong>– Although serum cortisol concentrations may be reduced due to loss of cortisol-binding globulin (CBG) in the urine, serum free cortisol concentrations are normal, and symptomatic hypocortisolism does not occur. (See <a class="local">'Glucocorticoid metabolism'</a> above.)</p><p></p><p class="headingAnchor" id="H7654305"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Nuhad Ismail, MD, who contributed to an earlier version of this topic review.</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Iglesias P, Bajo MA, Selgas R, Díez JJ. Thyroid dysfunction and kidney disease: An update. Rev Endocr Metab Disord 2017; 18:131.</a></li><li><a class="nounderline abstract_t">Li LZ, Hu Y, Ai SL, et al. The relationship between thyroid dysfunction and nephrotic syndrome: a clinicopathological study. Sci Rep 2019; 9:6421.</a></li><li><a class="nounderline abstract_t">Afrasiabi MA, Vaziri ND, Gwinup G, et al. Thyroid function studies in the nephrotic syndrome. Ann Intern Med 1979; 90:335.</a></li><li><a class="nounderline abstract_t">Gavin LA, McMahon FA, Castle JN, Cavalieri RR. Alterations in serum thyroid hormones and thyroxine-binding globulin in patients with nephrosis. J Clin Endocrinol Metab 1978; 46:125.</a></li><li><a class="nounderline abstract_t">Feinstein EI, Kaptein EM, Nicoloff JT, Massry SG. Thyroid function in patients with nephrotic syndrome and normal renal function. Am J Nephrol 1982; 2:70.</a></li><li><a class="nounderline abstract_t">Dagan A, Cleper R, Krause I, et al. Hypothyroidism in children with steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 2012; 27:2171.</a></li><li><a class="nounderline abstract_t">Chopra IJ, Williams DE, Orgiazzi J, Solomon DH. Opposite effects of dexamethasone on serum concentrations of 3,3',5'-triiodothyronine (reverse T3) and 3,3'5-triiodothyronine (T3). J Clin Endocrinol Metab 1975; 41:911.</a></li><li><a class="nounderline abstract_t">Kaptein EM. Thyroid function in renal failure. Contrib Nephrol 1986; 50:64.</a></li><li><a class="nounderline abstract_t">Illies F, Wingen AM, Bald M, Hoyer PF. Autoimmune thyroiditis in association with membranous nephropathy. J Pediatr Endocrinol Metab 2004; 17:99.</a></li><li><a class="nounderline abstract_t">Weetman AP, Pinching AJ, Pussel BA, et al. Membranous glomerulonephritis and autoimmune thyroid disease. Clin Nephrol 1981; 15:50.</a></li><li><a class="nounderline abstract_t">Horvath F Jr, Teague P, Gaffney EF, et al. Thyroid antigen associated immune complex glomerulonephritis in Graves' disease. Am J Med 1979; 67:901.</a></li><li><a class="nounderline abstract_t">Becker BA, Fenves AZ, Breslau NA. Membranous glomerulonephritis associated with Graves' disease. Am J Kidney Dis 1999; 33:369.</a></li><li><a class="nounderline abstract_t">Ploth DW, Fitz A, Schnetzler D, et al. Thyroglobulin-anti-thyroglobulin immune complex glomerulonephritis complicating radioiodine therapy. Clin Immunol Immunopathol 1978; 9:327.</a></li><li><a class="nounderline abstract_t">Gondil VS, Chandrasekaran A, Rastogi A, et al. Proteinuria in Severe Hypothyroidism: A Prospective Study. J Clin Endocrinol Metab 2021; 106:e749.</a></li><li><a class="nounderline abstract_t">Weerakkody RM, Lokuliyana PN. Severe hypothyroidism presenting as reversible proteinuria: two case reports. J Med Case Rep 2019; 13:270.</a></li><li><a class="nounderline abstract_t">Junglee NA, Scanlon MF, Rees DA. Increasing thyroxine requirements in primary hypothyroidism: don't forget the urinalysis! J Postgrad Med 2006; 52:201.</a></li><li><a class="nounderline abstract_t">Benvenga S, Vita R, Di Bari F, et al. Do Not Forget Nephrotic Syndrome as a Cause of Increased Requirement of Levothyroxine Replacement Therapy. Eur Thyroid J 2015; 4:138.</a></li><li><a class="nounderline abstract_t">Benido Silva V, Pereira MT, Moreira CL, et al. Nephrotic Syndrome as a Cause of Transient Clinical Hypothyroidism. Case Rep Endocrinol 2021; 2021:5523929.</a></li><li><a class="nounderline abstract_t">Guo QY, Zhu QJ, Liu YF, et al. Steroids combined with levothyroxine to treat children with idiopathic nephrotic syndrome: a retrospective single-center study. Pediatr Nephrol 2014; 29:1033.</a></li><li><a class="nounderline abstract_t">Alon U, Chan JC. Calcium and vitamin D homeostasis in the nephrotic syndrome: current status. Nephron 1984; 36:1.</a></li><li><a class="nounderline abstract_t">Sato KA, Gray RW, Lemann J Jr. Urinary excretion of 25-hydroxyvitamin D in health and the nephrotic syndrome. J Lab Clin Med 1982; 99:325.</a></li><li><a class="nounderline abstract_t">Barragry JM, France MW, Carter ND, et al. Vitamin-D metabolism in nephrotic syndrome. Lancet 1977; 2:629.</a></li><li><a class="nounderline abstract_t">Auwerx J, De Keyser L, Bouillon R, De Moor P. Decreased free 1,25-dihydroxycholecalciferol index in patients with the nephrotic syndrome. Nephron 1986; 42:231.</a></li><li><a class="nounderline abstract_t">Koenig KG, Lindberg JS, Zerwekh JE, et al. Free and total 1,25-dihydroxyvitamin D levels in subjects with renal disease. Kidney Int 1992; 41:161.</a></li><li><a class="nounderline abstract_t">Banerjee S, Basu S, Akhtar S, et al. Free vitamin D levels in steroid-sensitive nephrotic syndrome and healthy controls. Pediatr Nephrol 2020; 35:447.</a></li><li><a class="nounderline abstract_t">Goldstein DA, Haldimann B, Sherman D, et al. Vitamin D metabolites and calcium metabolism in patients with nephrotic syndrome and normal renal function. J Clin Endocrinol Metab 1981; 52:116.</a></li><li><a class="nounderline abstract_t">Freundlich M, Bourgoignie JJ, Zilleruelo G, et al. Calcium and vitamin D metabolism in children with nephrotic syndrome. J Pediatr 1986; 108:383.</a></li><li><a class="nounderline abstract_t">Malluche HH, Goldstein DA, Massry SG. Osteomalacia and hyperparathyroid bone disease in patients with nephrotic syndrome. J Clin Invest 1979; 63:494.</a></li><li><a class="nounderline abstract_t">Korkor A, Schwartz J, Bergfeld M, et al. Absence of metabolic bone disease in adult patients with the nephrotic syndrome and normal renal function. J Clin Endocrinol Metab 1983; 56:496.</a></li><li><a class="nounderline abstract_t">Mountokalakis Th, Virvidakis C, Singhellakis P, et al. Intestinal calcium absorption in the nephrotic syndrome. Ann Intern Med 1977; 86:746.</a></li><li><a class="nounderline abstract_t">Lim P, Jacob E, Tock EP, Pwee HS. Calcium and phosphorus metabolism in nephrotic syndrome. Q J Med 1977; 46:327.</a></li><li><a class="nounderline abstract_t">Mizokuchi M, Kubota M, Tomino Y, Koide H. Vitamin D metabolism in nephrotic rats. Contrib Nephrol 1991; 90:139.</a></li><li><a class="nounderline abstract_t">Khamiseh G, Vaziri ND, Oveisi F, et al. Vitamin D absorption, plasma concentration and urinary excretion of 25-hydroxyvitamin D in nephrotic syndrome. Proc Soc Exp Biol Med 1991; 196:210.</a></li><li><a class="nounderline abstract_t">Haldimann B, Trechsel U. Vitamin D replacement therapy in patients with the nephrotic syndrome. Miner Electrolyte Metab 1983; 9:154.</a></li><li class="breakAll">Bernard D. Metabolic abnormalities in the nephrotic syndrome: Pathophysiology and complications. In: Nephrotic Syndrome, Brenner BM, Stein JH (Eds), Churchill Livingstone, New York 1982. p.85.</li><li><a class="nounderline abstract_t">Pezzuti IL, Silva IN, Albuquerque CT, et al. Adrenal insufficiency in association with congenital nephrotic syndrome: a case report. J Pediatr Endocrinol Metab 2014; 27:565.</a></li><li><a class="nounderline abstract_t">Warady BA, Howard CP, Hellerstein S, et al. Congenital nephrosis in association with hypothyroidism and hypoadrenocorticism. Pediatr Nephrol 1993; 7:79.</a></li><li><a class="nounderline abstract_t">Linhares ND, Arantes RR, Araujo SA, Pena SDJ. Nephrotic syndrome and adrenal insufficiency caused by a variant in SGPL1. Clin Kidney J 2018; 11:462.</a></li></ol></div><div id="topicVersionRevision">Topic 3104 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27864708" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Thyroid dysfunction and kidney disease: An update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31015507" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The relationship between thyroid dysfunction and nephrotic syndrome: a clinicopathological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/106751" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Thyroid function studies in the nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/109453" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Alterations in serum thyroid hormones and thyroxine-binding globulin in patients with nephrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7180903" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Thyroid function in patients with nephrotic syndrome and normal renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22167590" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hypothyroidism in children with steroid-resistant nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1242390" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Opposite effects of dexamethasone on serum concentrations of 3,3',5'-triiodothyronine (reverse T3) and 3,3'5-triiodothyronine (T3).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3100133" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Thyroid function in renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14960028" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Autoimmune thyroiditis in association with membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6894269" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Membranous glomerulonephritis and autoimmune thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/583094" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Thyroid antigen associated immune complex glomerulonephritis in Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10023652" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Membranous glomerulonephritis associated with Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/342161" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Thyroglobulin-anti-thyroglobulin immune complex glomerulonephritis complicating radioiodine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33245744" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Proteinuria in Severe Hypothyroidism: A Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31455390" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Severe hypothyroidism presenting as reversible proteinuria: two case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16855322" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Increasing thyroxine requirements in primary hypothyroidism: don't forget the urinalysis!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26280000" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Do Not Forget Nephrotic Syndrome as a Cause of Increased Requirement of Levothyroxine Replacement Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34513097" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Nephrotic Syndrome as a Cause of Transient Clinical Hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24389651" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Steroids combined with levothyroxine to treat children with idiopathic nephrotic syndrome: a retrospective single-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6361594" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Calcium and vitamin D homeostasis in the nephrotic syndrome: current status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6977006" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Urinary excretion of 25-hydroxyvitamin D in health and the nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/71448" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Vitamin-D metabolism in nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3753749" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Decreased free 1,25-dihydroxycholecalciferol index in patients with the nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1593853" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Free and total 1,25-dihydroxyvitamin D levels in subjects with renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31845055" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Free vitamin D levels in steroid-sensitive nephrotic syndrome and healthy controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6969729" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Vitamin D metabolites and calcium metabolism in patients with nephrotic syndrome and normal renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3485195" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Calcium and vitamin D metabolism in children with nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/429568" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Osteomalacia and hyperparathyroid bone disease in patients with nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6822651" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Absence of metabolic bone disease in adult patients with the nephrotic syndrome and normal renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/869355" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Intestinal calcium absorption in the nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/303365" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Calcium and phosphorus metabolism in nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1659966" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Vitamin D metabolism in nephrotic rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1990409" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Vitamin D absorption, plasma concentration and urinary excretion of 25-hydroxyvitamin D in nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6308412" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Vitamin D replacement therapy in patients with the nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6308412" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Vitamin D replacement therapy in patients with the nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24633749" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Adrenal insufficiency in association with congenital nephrotic syndrome: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8439487" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Congenital nephrosis in association with hypothyroidism and hypoadrenocorticism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30090628" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Nephrotic syndrome and adrenal insufficiency caused by a variant in SGPL1.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
